The main sphere of activity of the enterprises comprising the Pharmstandard group of companies, are developing and manufacturing of high-quality modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients.
The most well known Pharmstandard products today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and Biosulin®. The Pharmstandard group of companies manufactures more than 250 pharmaceutical products, including medicines for the treatment of cardio-vascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, contagious diseases, metabolic disorders, cancer and other diseases. More than 100 Pharmstandard products (taking into account all forms and dosages) are included in the list of Vital and Essential Pharmaceuticals.
In the period from 2004 to 2011 more than 60 new pharmaceutical products were developed by Pharmstandard, in co-operation with the leading Russian scientific centres. Pharmstandard is a participant in a joint bio-engineering project, Generium, whose objective is the development of socially significant pharmaceutical products within the framework of the state program of import substitution.
By 2011 the Ñompany's aggregate production capacity has reached more than 1,46 billion packages per year. The production capacity of the Pharmstandard group of companies comprises four modern pharmaceutical plants: JSC Pharmstandard-Leksredstva (Kursk), JSC Pharmstandard-UfaVita (Ufa), JSC Pharmstandard-Tomskhimpharm (Tomsk), JSC Pharmstandard-Biolek (Kharkov, Ukraine) and the medical equipment and tools plant JSC TZMOI (Tyumen); Pharmstandard LLC is responsible for the purchase and supply of raw materials for manufacturing of pharmaceutical products at the production facilities of the Pharmstandard group of companies.
All the production facilities of the Pharmstandard group of companies fully comply with Russian national standards, while six production lines at JSC Pharmstandard-Leksredstva have already received certificates of compliance with the EU GMP standards. All the plants are expected to convert to European GMP standards by 2014, according to the schedule approved by the company's management.
On 4 May 2007 Pharmstandard placed its shares during IPO on Russian Trading System (RTS), Moscow Interbank Currency Exchange (MICEX) and Global Depositary Receipts (GDR) at London Stock Exchange (LSE).
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.